Displaying drugs 11076 - 11100 of 11788 in total
Bifidobacterium Longum Infantis 35624
Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and irritable bowel syndrome.[A259872, A259877]
Investigational
Matched Description: … Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal …
Chlorophyll B
A light, silvery, metallic element. It has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. Its salts are essential in nutrition, being required for the activity of many enzymes, especially those concerned with oxidative phosphorylation. It is a component of both intra- and extracellular fluids and is...
Experimental
Matched Description: … A light, silvery, metallic element. ... It is a component of both intra- and extracellular fluids and is excreted in the urine and feces. …
MPI-674
MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. It is...
Investigational
Matched Description: … MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability ... AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and …
LNP-nCoVsaRNA Vaccine
LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly...
Investigational
Matched Description: … LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV ... As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity …
Liatermin
Investigational
Phosphonotyrosine
An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis. [PubChem]
Experimental
Matched Description: … Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly …
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Matched Description: … WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin …
Indoprofen
A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.
Withdrawn
Matched Description: … A drug that has analgesic and anti-inflammatory properties. …
PF-232798
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Matched Description: … PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple …
Fenpyroximate
Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania).
Investigational
Matched Description: … clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a …
Ladostigil
Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Investigational
Matched Description: … Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety …
Lazertinib
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Investigational
Matched Description: … Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib …
Veliflapon
Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).
Investigational
Matched Description: … clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a …
Nadecnemab
Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).
Investigational
Matched Description: … Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and …
Maplirpacept
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory …
BEA-17
BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. It is under investigation for the treatment of glioblastoma.
Investigational
Matched Description: … BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. …
CYT997
CYT997 is an orally available vascular argeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias.
Investigational
Matched Description: … orally available vascular argeting and cytotoxic agent that has proven effective in animal models of a …
LY2140023
LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications...
Investigational
Matched Description: … LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for …
Larcaviximab
Investigational
TMP
Experimental
Palazestrant
Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).
Investigational
Mazorelvimab
Investigational
KD3010
KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Investigational
Matched Description: … KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for …
Solabegron
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
Investigational
Matched Description: … Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive …
CHIR-124
CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Experimental
Matched Description: … CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in …
Displaying drugs 11076 - 11100 of 11788 in total